End­points ex­clu­sive: Bob Nelsen's Re­silience snags Flori­da CD­MO work­ing with the De­fense De­part­ment on Covid-19 an­ti­body

Re­silience has on­ly been in ex­is­tence for less than six months, but Bob Nelsen’s next-gen man­u­fac­tur­ing play has made plen­ty of moves short­ly af­ter de­but­ing with an $800 mil­lion launch round. Now, the biotech look­ing to change drug man­u­fac­tur­ing is pick­ing up a Flori­da CD­MO part­nered with the De­part­ment of De­fense on a Covid-19 an­ti­body.

Re­silience is ac­quir­ing CD­MO Ol­o­gy Bioser­vices in a deal that will add two man­u­fac­tur­ing sites to the bi­coastal biotech’s foot­print as well as a gov­ern­ment-backed mon­o­clon­al an­ti­body, a source close to the mat­ter said Mon­day. Fi­nan­cial terms of the deal were not avail­able.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER